Neuroblastoma Genomic Discovery Gateway To Potential Therapies
This article was originally published in Scrip
Scientists at NEO New Oncology AG and the University of Cologne have identified previously unknown genomic alterations in neuroblastoma which may help improve tumor diagnostics and potentially leading to the development of new therapies for the pediatric disease.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.